← Back to all trials
Not Yet Recruiting
NCT07907783
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
Conditions: Androgenetic Alopecia
Sex: Female
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 200
Sponsor: Pelage Pharmaceuticals, Inc.
Summary
The study is designed to evaluate safety and efficacy of PP405 in adult female participants with androgenetic alopecia
Eligibility Criteria
Inclusion Criteria:
1. Female (assigned at birth) aged 18 to 65 years, inclusive at time of consent.
2. Able and willing to provide written informed consent
3. Must have been experiencing Androgenetic Alopecia (AGA) for at least 6 months prior to screening.
4. Have a Savin Scale stages I-3, I-4, II-1, or II-2
5. Agree to comply with protocol procedures
Exclusion Criteria:
1. Concomitant diagnosis of non-AGA forms of alopecia.
2. Use of other hair loss treatments within periods specified in protocol.
3. Use of excluded medications as specified in protocol.
4. Diagnosis of other medical conditions as specified in protocol.
5. Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results.
Source: ClinicalTrials.gov (NCT07907783). StuddyBuddy aggregates publicly available trial information.
